Chlamydia pneumoniae is responsible for respiratory tract infections of both upper and lower respiratory tract. Although this bacterium is one of the most wide-spread pathogens of man, there are limited data on the antibiotic treatment of C. pneumoniae infections. The aim of this study has been to evaluate the in vitro activity of thiamphenicol glycinate acetylcysteinate (TGA, CAS 20192-91-0) in comparison with molecules with established activity against C. pneumoniae, as well as macrolides and quinolones. The results have shown that TGA and clarithromycin (CAS 81103-11-9) are the most active drugs tested, but it is important to underline that the minimal inhibitory concentration (MIC) ranges of TGA are very much lower than the breakpoint of thlamphenicol for the respiratory pathogens. In conclusion, the good antimicrobial in vitro activity of TGA against C. pneumoniae together with its in vivo characteristics, in particular the high concentration reached in lung and the combination with the mucolytic agent N-acetylcysteine (NAC, CAS 616-91-1), can make a valid choice in the treatment of respiratory tract infections caused by C. pneumoniae. These findings need further evaluation by clinical studies.

Antimicrobial activity of thyamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae / A. Lombardi, L. Drago, E. De Vecchi, B. Mombelli, M.R. Gismondo. - In: ARZNEIMITTEL-FORSCHUNG. - ISSN 0004-4172. - 51:3(2001), pp. 264-267.

Antimicrobial activity of thyamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae

L. Drago
Secondo
;
E. De Vecchi;M.R. Gismondo
Ultimo
2001

Abstract

Chlamydia pneumoniae is responsible for respiratory tract infections of both upper and lower respiratory tract. Although this bacterium is one of the most wide-spread pathogens of man, there are limited data on the antibiotic treatment of C. pneumoniae infections. The aim of this study has been to evaluate the in vitro activity of thiamphenicol glycinate acetylcysteinate (TGA, CAS 20192-91-0) in comparison with molecules with established activity against C. pneumoniae, as well as macrolides and quinolones. The results have shown that TGA and clarithromycin (CAS 81103-11-9) are the most active drugs tested, but it is important to underline that the minimal inhibitory concentration (MIC) ranges of TGA are very much lower than the breakpoint of thlamphenicol for the respiratory pathogens. In conclusion, the good antimicrobial in vitro activity of TGA against C. pneumoniae together with its in vivo characteristics, in particular the high concentration reached in lung and the combination with the mucolytic agent N-acetylcysteine (NAC, CAS 616-91-1), can make a valid choice in the treatment of respiratory tract infections caused by C. pneumoniae. These findings need further evaluation by clinical studies.
English
Thyamphenicol-glycinate-acetylcysteinate ; Chlamydia pneumoniae
Settore MED/07 - Microbiologia e Microbiologia Clinica
Articolo
Comitato scientifico
2001
Editio Cantor KG
51
3
264
267
Pubblicato
Periodico con rilevanza internazionale
info:eu-repo/semantics/article
Antimicrobial activity of thyamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae / A. Lombardi, L. Drago, E. De Vecchi, B. Mombelli, M.R. Gismondo. - In: ARZNEIMITTEL-FORSCHUNG. - ISSN 0004-4172. - 51:3(2001), pp. 264-267.
none
Prodotti della ricerca::01 - Articolo su periodico
5
262
Article (author)
no
A. Lombardi, L. Drago, E. De Vecchi, B. Mombelli, M.R. Gismondo
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/22317
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 5
social impact